JP2014516036A5 - - Google Patents

Download PDF

Info

Publication number
JP2014516036A5
JP2014516036A5 JP2014511553A JP2014511553A JP2014516036A5 JP 2014516036 A5 JP2014516036 A5 JP 2014516036A5 JP 2014511553 A JP2014511553 A JP 2014511553A JP 2014511553 A JP2014511553 A JP 2014511553A JP 2014516036 A5 JP2014516036 A5 JP 2014516036A5
Authority
JP
Japan
Prior art keywords
beta
acid
phe
peptide product
tic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014511553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516036A (ja
JP6148228B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/038429 external-priority patent/WO2012158962A2/en
Publication of JP2014516036A publication Critical patent/JP2014516036A/ja
Publication of JP2014516036A5 publication Critical patent/JP2014516036A5/ja
Application granted granted Critical
Publication of JP6148228B2 publication Critical patent/JP6148228B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014511553A 2011-05-18 2012-05-17 改善されたペプチド製剤 Active JP6148228B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161487636P 2011-05-18 2011-05-18
US201161487638P 2011-05-18 2011-05-18
US61/487,638 2011-05-18
US61/487,636 2011-05-18
US201161543721P 2011-10-05 2011-10-05
US201161543725P 2011-10-05 2011-10-05
US61/543,721 2011-10-05
US61/543,725 2011-10-05
PCT/US2012/038429 WO2012158962A2 (en) 2011-05-18 2012-05-17 Improved peptide pharmaceuticals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017008902A Division JP6883912B2 (ja) 2011-05-18 2017-01-20 改善されたペプチド製剤

Publications (3)

Publication Number Publication Date
JP2014516036A JP2014516036A (ja) 2014-07-07
JP2014516036A5 true JP2014516036A5 (enExample) 2015-07-09
JP6148228B2 JP6148228B2 (ja) 2017-06-14

Family

ID=47177640

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2014511553A Active JP6148228B2 (ja) 2011-05-18 2012-05-17 改善されたペプチド製剤
JP2017008902A Active JP6883912B2 (ja) 2011-05-18 2017-01-20 改善されたペプチド製剤
JP2019103108A Active JP6929610B2 (ja) 2011-05-18 2019-05-31 改善されたペプチド製剤
JP2020174102A Pending JP2021020925A (ja) 2011-05-18 2020-10-15 改善されたペプチド製剤
JP2022177489A Pending JP2023022045A (ja) 2011-05-18 2022-11-04 改善されたペプチド製剤
JP2024205047A Pending JP2025043342A (ja) 2011-05-18 2024-11-25 改善されたペプチド製剤

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017008902A Active JP6883912B2 (ja) 2011-05-18 2017-01-20 改善されたペプチド製剤
JP2019103108A Active JP6929610B2 (ja) 2011-05-18 2019-05-31 改善されたペプチド製剤
JP2020174102A Pending JP2021020925A (ja) 2011-05-18 2020-10-15 改善されたペプチド製剤
JP2022177489A Pending JP2023022045A (ja) 2011-05-18 2022-11-04 改善されたペプチド製剤
JP2024205047A Pending JP2025043342A (ja) 2011-05-18 2024-11-25 改善されたペプチド製剤

Country Status (8)

Country Link
US (4) US10010617B2 (enExample)
EP (3) EP4286400A3 (enExample)
JP (6) JP6148228B2 (enExample)
KR (2) KR102512178B1 (enExample)
CN (2) CN103796666B (enExample)
AU (4) AU2012255116B2 (enExample)
CA (1) CA2836573C (enExample)
WO (2) WO2012158962A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4286400A3 (en) * 2011-05-18 2024-06-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
CA3134906A1 (en) * 2011-05-18 2012-11-22 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
MX354705B (es) 2011-09-23 2018-03-16 Novo Nordisk As Analogos de glucagon novedosos.
MX349035B (es) 2012-05-17 2017-07-07 Extend Biosciences Inc Portadores para el suministro mejorado de farmaco.
WO2014081872A1 (en) 2012-11-20 2014-05-30 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
EP2922877B1 (en) * 2012-11-20 2018-09-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
BR112015025464A2 (pt) 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
CN117582516A (zh) * 2014-05-28 2024-02-23 梅德瑞斯糖尿病有限责任公司 针对胰岛素抵抗的改良肽药物
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
EP3180021A4 (en) * 2014-08-11 2018-04-18 Albany Medical College Myristoylated leptin-related peptides and uses thereof
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
CN110545836A (zh) 2017-01-24 2019-12-06 马克雷根有限公司 用载脂蛋白模拟物治疗与年龄有关的黄斑变性和其他眼部疾病
EP3570888A1 (en) 2017-03-03 2019-11-27 MacRegen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
US11512111B2 (en) * 2017-11-27 2022-11-29 The University Of Hong Kong Yeats inhibitors and methods of use thereof
AU2019205905B2 (en) * 2018-01-03 2024-12-12 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of NASH and other disorders
US11911445B2 (en) 2018-01-23 2024-02-27 Gila Therapeutics, Inc. Peptide YY pharmaceutical formulations, compositions, and methods
TWI764248B (zh) * 2019-08-23 2022-05-11 大陸商四川海思科製藥有限公司 肽醯胺類組合物及其製備
CA3168001A1 (en) * 2020-02-21 2021-08-26 Spitfire Pharma Llc Glp-1r and gcgr agonists, formulations, and methods of use
CN117202924A (zh) 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
WO2022270482A1 (ja) * 2021-06-24 2022-12-29 国立大学法人茨城大学 糖鎖固定化ポリマー粒子及びその製造方法
KR102844771B1 (ko) * 2022-07-22 2025-08-12 주식회사 아이큐어비앤피 테리파라타이드를 포함하는 골다공증 예방 또는 치료를 위한 경구용 약학적 조성물 및 이의 제조방법
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR18245E (fr) 1913-01-10 1914-02-28 Gedeon Guibal Flotteur avec index indicateur de niveau, pour chaudières à vapeur et autres appareils, permettant de connaitre le niveau d'un liquide quelconque à une hauteur inférieur au niveau lui-meme
US3219656A (en) 1963-08-12 1965-11-23 Rohm & Haas Alkylpolyalkoxyalkyl glucosides and process of preparation therefor
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
ATE37552T1 (de) * 1982-10-18 1988-10-15 Ici Plc Peptid- und pseudopeptid-derivate.
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DK149776C (da) 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
AT382381B (de) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JPS63152393A (ja) * 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
SE9401596D0 (sv) * 1994-05-06 1994-05-06 Astra Ab New compounds
JPH1160598A (ja) * 1997-08-15 1999-03-02 Asahi Glass Co Ltd オピオイド様ペプチド
US20010010919A1 (en) * 1998-10-13 2001-08-02 David K. Grandy Opioid antagonists and methods of their use
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
RU2181729C1 (ru) * 2000-09-20 2002-04-27 Калюжин Олег Витальевич Производные мурамовой кислоты
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6864069B2 (en) 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
US6881829B2 (en) * 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
AU2003220380A1 (en) * 2003-03-19 2004-11-19 Bristol-Myers Squibb Company CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH Alpha-HELIX STABILIZERS
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20110257096A1 (en) 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
ITRM20040607A1 (it) 2004-12-15 2005-03-15 Biogen S R L Analoghi della dermorfina ad attivita' analgesica.
US7776819B2 (en) * 2005-03-03 2010-08-17 The Board Of Trustees Of The University Of Illinois Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization
CA2607566A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
WO2007002465A2 (en) 2005-06-23 2007-01-04 Rapid Pharmaceuticals, Llc Stabilizing alkylglycoside compositions and methods thereof
HUE035853T2 (en) * 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
WO2007060692A2 (en) 2005-11-24 2007-05-31 Brain N' Beyond Biotech Pvt. Ltd. Compositions for increasing bioavailability of peptides or proteins and method thereof
US7425542B2 (en) 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) * 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
BRPI0814962B8 (pt) * 2007-08-01 2021-05-25 Chugai Pharmaceutical Co Ltd métodos in vitro para determinar se um composto candidato é um agonista de longa duração ou de curta duração de um receptor acoplado à proteína g, polipeptídeo, seu uso e composição farmacêutica
EP2052736A1 (en) * 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
CA2728284C (en) 2008-06-17 2019-09-10 Richard D. Dimarchi Glucagon/glp-1 receptor co-agonists
EP4286400A3 (en) * 2011-05-18 2024-06-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
CA3134906A1 (en) 2011-05-18 2012-11-22 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
EP2922877B1 (en) 2012-11-20 2018-09-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
WO2014081872A1 (en) 2012-11-20 2014-05-30 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
CN117582516A (zh) 2014-05-28 2024-02-23 梅德瑞斯糖尿病有限责任公司 针对胰岛素抵抗的改良肽药物
AU2019205905B2 (en) * 2018-01-03 2024-12-12 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of NASH and other disorders
CA3168001A1 (en) * 2020-02-21 2021-08-26 Spitfire Pharma Llc Glp-1r and gcgr agonists, formulations, and methods of use

Similar Documents

Publication Publication Date Title
JP2016501204A5 (enExample)
EP2709645B1 (en) Improved peptide pharmaceuticals
JP2014516037A5 (enExample)
KR102011924B1 (ko) 인슐린 저항성에 대한 개선된 펩티드 제약
AU2020203609B2 (en) Improved peptide pharmaceuticals for insulin resistance
KR102365582B1 (ko) 인슐린 저항성에 대한 개선된 펩티드 약제
AU2003235401B2 (en) Medicinal compositions containing ghrelin
BE1003752A4 (fr) Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments.
EP2559697B1 (en) Novel lipid peptide and hydrogel
EP2427475B1 (en) High penetration prodrug compositions of peptides and peptide-related compounds
HK1221477A1 (zh) 多肽及相关化合物的透皮给药系统
JP2009533459A (ja) 共有結合する化合物の鎮痛作用の増強と、有害な副作用の減衰と、前記化合物の乱用の予防とのための組成物及び方法
WO2007096662A3 (en) Cancer imaging and treatment
CA3163522A1 (en) Glp2 receptor agonists and methods of use
JP2011523415A (ja) 新規な二重標的化抗腫瘍複合体
WO2007112348A2 (en) Prodrug composition
ES2869430T3 (es) Procedimiento para preparar D-arginil-2,6-dimetil-L-tirosil-L-lisil-L-fenilalaninamida
AU2008339610B2 (en) Methods of peptide modification
Wang et al. Discovery, SAR, synthesis, pharmacokinetic and biochemical characterization of A-192411: a novel fungicidal lipopeptide-(I)
EP1348714B1 (en) Polypeptide useful as anti-allergic/antiasthmatic, methods for the preparation thereof and pharmaceutical compositions containing such polypeptide and their use
IE893990L (en) Competitive gonadoliberin antagonists
US20060160989A1 (en) Polypeptide useful as antiallergic/antiasthmatic activity, methods for the preparation thereof, pharmaceutical compositions containing such polypeptide and use thereof
JPH0925240A (ja) 医薬組成物
HK1137412A (en) Transdermal delivery systems of peptides and related compounds
NZ617824B2 (en) Improved peptide pharmaceuticals for insulin resistance